Publications by authors named "Tim P Green"

Claim this Profile
S
Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.
Christopher J Morrow, Mohammad Ghattas, Christopher Smith, Heinz Bönisch, Richard A Bryce, Tim P Green

Cancer Res· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function.
Amanda Gatesman Ammer, Laura C Kelley, Karen E Hayes, Jason V Evans, Lesly Ann Lopez-Skinner, Tim P Green

J Cancer Sci Ther· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
Tim P Green, Mike Fennell, Robin Whittaker, Jon Curwen, Vivien Jacobs

Mol Oncol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.
N V Rajeshkumar, Aik Choon Tan, Elizabeth De Oliveira, Chris Womack, Helen Wombwell, Tim P Green

Clin Cancer Res· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.
Phillip R Purnell, Philip C Mack, Clifford G Tepper, Christopher P Evans, Tim P Green

J Thorac Oncol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts.
Teun J de Vries, Margriet G Mullender, Marion A van Duin, Cornelis M Semeins, Neil James, Tim P Green

Mol Cancer Res· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model.
Bryan Serrels, Alan Serrels, Susan M Mason, Christine Baldeschi, Gabrielle H Ashton, Tim P Green

Carcinogenesis· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer.
Oliver Gautschi, Clifford G Tepper, Phillip R Purnell, Yoshihiro Izumiya, Christopher P Evans, Tim P Green

Cancer Res· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells.
Stephen Hiscox, Nicola J Jordan, Liam Morgan, Tim P Green, Robert I Nicholson

Clin Exp Metastasis· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.
Matthew H Herynk, Amanda R Beyer, Yukun Cui, Heidi Weiss, Elizabeth Anderson, Tim P Green

Mol Cancer Ther· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.
Laurent F Hennequin, Jack Allen, Jason Breed, Jon Curwen, Michael Fennell, Tim P Green

J Med Chem· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.
Stephen Hiscox, Liam Morgan, Tim P Green, Denise Barrow, Julia Gee

Breast Cancer Res Treat· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src.
Patrick A Plé, Tim P Green, Laurent F Hennequin, Jon Curwen, Michael Fennell

J Med Chem· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis